T
Tempei Miyaji
Researcher at University of Tokyo
Publications - 56
Citations - 1073
Tempei Miyaji is an academic researcher from University of Tokyo. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 12, co-authored 38 publications receiving 790 citations. Previous affiliations of Tempei Miyaji include Tohoku University.
Papers
More filters
Journal ArticleDOI
The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events
Takashi Kawaguchi,Kanako Azuma,Motohiko Sano,Soan Kim,Yosuke Kawahara,Yoko Sano,Tomohide Shimodaira,Keiichiro Ishibashi,Tempei Miyaji,Ethan Basch,Takuhiro Yamaguchi +10 more
TL;DR: There is underestimation in the assessment of adverse events in Japan, and that the Japanese version of the PRO-CTCAE had acceptable reliability and validity for common and clinically important symptoms.
Journal ArticleDOI
Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tempei Miyaji,Yukiko Iioka,Yukiko Iioka,Yujiro Kuroda,Daigo Yamamoto,Satoru Iwase,Yasushi Goto,Masahiro Tsuboi,Hiroki Odagiri,Yu Tsubota,Takashi Kawaguchi,Naoko Sakata,Ethan Basch,Takuhiro Yamaguchi,Takuhiro Yamaguchi +14 more
TL;DR: The study provides preliminary evidence supporting the linguistic validity of the Japanese version of PRO-CTCAE, and further cognitive interviewing is warranted for PRO- CTCAE items relating to sexuality and anxiety and for response options on severity attribute items.
Journal ArticleDOI
Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial
Hironori Ishigami,Yoshiyuki Fujiwara,Ryoji Fukushima,Atsushi Nashimoto,Hiroshi Yabusaki,Motohiro Imano,Haruhiko Imamoto,Yasuhiro Kodera,Yoshikazu Uenosono,Kenji Amagai,Shigenori Kadowaki,Hiroto Miwa,Hironori Yamaguchi,Takuhiro Yamaguchi,Tempei Miyaji,Joji Kitayama +15 more
TL;DR: This trial failed to show statistical superiority over standard systemic chemotherapy in overall survival, but the exploratory analyses suggested possible clinical benefits of intraperitoneal paclitaxel for gastric cancer.
Journal ArticleDOI
Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)
Satoru Iwase,Takashi Kawaguchi,Daisuke Yotsumoto,Takako Doi,Kyuichiro Miyara,Hiroki Odagiri,K. Kitamura,Keisuke Ariyoshi,Tempei Miyaji,Hiroto Ishiki,Kenichi Inoue,Chizuko Tsutsumi,Yoshiaki Sagara,Takuhiro Yamaguchi,Takuhiro Yamaguchi +14 more
TL;DR: IP may control moderate-severe CRF in breast cancer patients, and changes in the worst level of fatigue, GFS, and current feeling of fatigue were significantly different between the intervention and control groups, whereas the change in the average feel of fatigue was not significantlyDifferent between groups.
Journal ArticleDOI
Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).
Shunsuke Ohnishi,Hidemichi Watari,Maki Kanno,Yoko Ohba,Satoshi Takeuchi,Tempei Miyaji,Shunsuke Oyamada,Eiji Nomura,Hidenori Kato,Toru Sugiyama,Masahiro Asaka,Noriaki Sakuragi,Takuhiro Yamaguchi,Takuhiro Yamaguchi,Yasuhito Uezono,Satoru Iwase +15 more
TL;DR: Rikkunshito provided additive effect for the prevention of CINV and anorexia in patients treated with cisplatin and appeared to be superior in the rikkunhito group from day 2 through day 6.